603520.SH
司太立
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.69
−1.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.4B | 2.4B | 2.2B | 2.1B |
| Cost of Revenue | 1.9B | 1.9B | 1.9B | 1.7B | 1.6B |
| Gross Profit | 539.5M | 503.6M | 456.7M | 533.3M | 512.5M |
| Operating Expenses | |||||
| R&D Expense | 137.4M | 128.2M | 140.7M | 134.6M | 132.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 121.0M | 117.7M | 117.5M | 127.9M | 145.5M |
| Selling & Marketing Expense | 139.3M | 133.6M | 127.0M | 99.1M | 70.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 491.8M | 464.2M | 509.1M | 476.5M | 477.3M |
| Cost and Expenses | 2.4B | 2.4B | 2.4B | 2.1B | 2.1B |
| Operating Income (EBIT) | 23.4M | 12.2M | (53.5M) | 49.2M | (55.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 18.4M | 7.0M | (57.2M) | 45.4M | (65.4M) |
| Income Tax Expense | 1.6M | (3.3M) | (8.1M) | 798.8K | 6.5M |
| Bottom Line | |||||
| Net Income | 16.8M | 10.2M | (49.1M) | 44.2M | (75.9M) |
| Earnings from Cont. Ops | 16.8M | 10.3M | (49.1M) | 44.6M | (71.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 16.8M | 10.2M | (49.1M) | 44.2M | (75.9M) |
| Per Share | |||||
| Basic EPS | CN¥0.05 | CN¥0.02 | (CN¥0.12) | CN¥0.13 | (CN¥0.22) |
| Diluted EPS | CN¥0.05 | CN¥0.02 | (CN¥0.12) | CN¥0.13 | (CN¥0.22) |
| Revenue Per Share | CN¥5.90 | CN¥4.78 | CN¥5.74 | CN¥6.45 | CN¥6.18 |
| Shares | |||||
| Basic Shares Outstanding | 419.1M | 511.4M | 409.2M | 340.2M | 344.8M |
| Diluted Shares Outstanding | 419.1M | 511.4M | 409.2M | 340.2M | 344.8M |
| Profitability Metrics | |||||
| EBITDA | — | 258.0M | 172.5M | 235.2M | 111.6M |
| D&A | — | 245.8M | 226.0M | 186.1M | 167.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026